SWOG-S1801: A Phase II Randomized Study of Adjuvant versus Neoadjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High Risk Melanoma

The purpose of this study is to compare outcomes of receiving the study drug either before and after or only after surgery for the patient’s type of cancer.

Learn more about the SWOG-S1801 trial or contact the Protocol Office at 484-628-8193.

ECOG/ACRIN-EA6134: A randomized phase III trial of dabrafenib + trametinib followed by ipilmumab + nivolumab at progression vs. ipilmumab + nivolumab followed by dabrafenib + trametinib at progression in patients with advanced BRAFV600 mutant melanoma

The purpose of this research study is to compare the good and bad effects of immunotherapy followed by BRAF inhibitor therapy when the disease becomes resistant to BRAF inhibitor therapy followed by immunotherapy.

Learn more about the ECOG/ACRIN-EA6134 trial or contact the Protocol Office at 484-628-8193.

ECOG/ACRIN-EA6141: Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma.

The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab together.

Learn more about the ECOG/ACRIN-EA6141 trial or call the Protocol Office at 484-628-8193.